This post is from a suggested group
Plasma Fractionation: Driving Innovation in Biopharmaceuticals
Plasma fractionation is a cornerstone process in modern biopharmaceutical manufacturing, enabling the production of life-saving therapies derived from human plasma. The process separates plasma into its key components—albumin, immunoglobulins, clotting factors, and other proteins—each serving a vital role in treating various medical conditions. With rising demand for plasma-derived products, particularly in immunology and critical care, plasma fractionation is emerging as a strategic focus for pharmaceutical companies, contract manufacturing organizations, and healthcare providers.
Growing Demand for Plasma-Derived Therapies
The global demand for plasma-derived products is expanding due to the rising prevalence of immune deficiencies, hemophilia, and rare bleeding disorders. Immunoglobulins remain the largest segment, driven by applications in primary immune deficiency diseases, autoimmune disorders, and neurology. Similarly, albumin demand continues to grow, especially in developing economies, for use in critical care and surgical settings. This increasing patient need is pushing biopharma companies to expand plasma…